Brief: Novartis Agrees To Acquire Pan-Mutant-Selective Pi3kα Inhibitor
20/03/2026 06:03
March 20 (Reuters) - NOVARTIS AG NOVN.S: AGREES TO ACQUIRE A PAN-MUTANT-SELECTIVE PI3KΑ INHIBITOR, STRENGTHENING ITS BREAST CANCER PIPELINE TO PAY $2 BILLION UPFRONT AND UP TO $1 BILLION IN MILESTONE PAYMENTS DEAL EXPECTED TO CLOSE IN H1 2026 SUBJECT TO REGULATORY APPROVALS SNV4818 CURRENTLY IN PHASE 1/2 CLINICAL STUDY FOR BREAST CANCER AND SOLID TUMORS AGREEMENT WITH SYNNOVATION THERAPEUTICS, LLC Source text: ID:nGNE1NJ8xn Further company coverage: NOVN.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'